Management of localized prostate cancer in senior adults: The crucial role of comorbidity

BJU International, Supplement

Volumn 101, Issue SUPPL. 2, 2008, Pages 16-22

  Fitzpatrick, John M ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Comorbidity; Hormone therapy; Localized prostate cancer; Radical prostatectomy; Radiotherapy; Senior adults

Indexed keywords

AGED; CLINICAL PRACTICE; COMORBIDITY; ELDERLY CARE; HUMAN; LIFE EXPECTANCY; MEDICAL DECISION MAKING; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 40149083892     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07487.x     Document Type: Review

References (32)

1. Surveillance Epidemiology and End Results (SEER). SEER data for 2000-2004. National Cancer Institute website. Available at: http://www.cancer. gov. Accessed January 2008
2. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005 293 : 2095 101
3. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003 21 : 2163 72. Reprinted with permission from American Society if Clinical Oncology
4. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998 280 : 975 80
5. Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 2002 168 : 525 9
6. Tewari A, Johnson CC, Divine G et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004 171 : 1513 9
7. National Comprehensive Cancer Network Oncology Guidelines 2007. Prostate cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/ prostate.pdf. Accessed January 2008
8. Heidenreich A, Aus G, Abbou CC et al. Guidelines on prostate cancer. European Association of Urology 2007. Available at: http://www.uroweb.org/ fileadmin/user_upload/Guidelines/07_Prostate_Cancer_2007.pdf. Accessed January 2008
9. Desch CE, Penberthy L, Newschaffer CJ et al. Factors that determine the treatment for local and regional prostate cancer. Med Care 1996 34 : 152 62
10. Bubolz T, Wasson JH, Lu-Yao G, Barry MJ. Treatments for prostate cancer in older men: 1984-1997. Urology 2001 58 : 977 82. 2001 © Reprinted with permission from Elsevier
11. Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 2005 8 : 22 30
12. Harlan LC, Potosky A, Gilliland FD et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 2001 93 : 1864 71
13. Schwartz KL, Alibhai SM, Tomlinson G, Naglie G, Krahn MD. Continued undertreatment of older men with localized prostate cancer. Urology 2003 62 : 860 5
14. Houterman S, Janssen-Heijnen ML, Verheij CD, Kil PJ, van den Berg HA, Coebergh JW. Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study. Prostate Cancer Prostatic Dis 2006 9 : 179 84
15. Harlan SR, Cooperberg MR, Elkin EP et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 2003 170 : 1804 7
16. Wong YN, Mitra N, Hudes G et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006 296 : 2683 93
17. Siddiqui SA, Sengupta S, Slezak JM et al. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol 2006 175 : 952 7
18. Walsh PC. The natural history of localized prostate cancer: a guide to therapy. In Walsh PC, Retick AB, Vaughan ED, Wein AJ eds, Campbell's Urology, 7th edn, Vol. 3. Philadelphia, PA : W.B. Saunders, 1998 : 2539 46 CB, Riedel ER, Bach PB et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002 346 : 1138 44
19. Alibhai SM, Leach M, Tomlinson G et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005 97 : 1525 32
20. Stanford JL, Feng Z, Hamilton AS et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000 283 : 354 60
21. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3477 consecutive radical retropubic prostatectomies. J Urol 2004 172 : 2227 31
22. Johnstone PA, Riffenburgh RH, Moul JW et al.,. Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. Int J Radiat Oncol Biol Phys 2003 55 : 964 9
23. Jani AB, Parikh SD, Vijayakumar S, Gratzle J. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urology 2005 65 : 1157 62
24. Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 2006 24 : 5298 304
25. Studer UE, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006 24 : 1868 76
26. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006 24 : 4448 56
27. D'Amico AV, Denham JW, Crook J et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007 25 : 2420 5
28. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007 99 : 1516 24
29. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002 87 : 3656 61
30. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000 163 : 181 6
31. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005 352 : 154 64
32. Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 2007 100 : 749 54